Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis.

Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis.

Muscle-specific tyrosine kinase (MuSK) autoantibodies are the hallmark of a form of myasthenia gravis (MG) that can challenge the neurologist and the experimentalist. The clinical disease can be difficult to treat effectively. MuSK autoantibodies affect the neuromuscular junction in several ways. Wh...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Phillips, W, Christadoss, P, Losen, M, Punga, A, Shigemoto, K, Verschuuren, J, Vincent, A
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	Academic Press Inc. 2015

Παρόμοια τεκμήρια

Myasthenia gravis with MuSK antibodies
ανά: Farrugia, M, κ.ά.
Έκδοση: (2005)

The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.
ανά: Koneczny, I, κ.ά.
Έκδοση: (2014)

The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis
ανά: Koneczny, I, κ.ά.
Έκδοση: (2014)

Potential mechanisms in MuSK-myasthenia gravis
ανά: Koneczny, I
Έκδοση: (2014)

MuSK-Myasthenia Gravis Unmasked by Hydroxychloroquine
ανά: Shalini Bhaskar, κ.ά.
Έκδοση: (2022-01-01)

Infantile Onset Myasthenia Gravis with MuSK Antibodies
ανά: J Gordon Millichap
Έκδοση: (2006-08-01)

The prevalence of MuSK antibody positive myasthenia gravis worldwide
ανά: Vincent, A, κ.ά.
Έκδοση: (2006)

Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.
ανά: McConville, J, κ.ά.
Έκδοση: (2004)

MuSK antibody-positive, seronegative myasthenia gravis in Korea.
ανά: Lee, J, κ.ά.
Έκδοση: (2006)

MuSK Antibody Positive Myasthenia Gravis Mimicking as Myositis
ανά: Nilesh Wagh, κ.ά.
Έκδοση: (2024-09-01)

MuSK-Associated Myasthenia Gravis: Clinical Features and Management
ανά: Carmelo Rodolico, κ.ά.
Έκδοση: (2020-07-01)

Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models
ανά: Jamie L. Lim, κ.ά.
Έκδοση: (2025-02-01)

MuSK-antibody-positive myasthenia gravis in a South Asian population.
ανά: Chang, T, κ.ά.
Έκδοση: (2009)

Anti-MuSK antibodies in a case of ocular myasthenia gravis.
ανά: Bennett, D, κ.ά.
Έκδοση: (2006)

Anti-MuSK antibody positive myasthenia gravis with childhood onset
ανά: Diana Epure, κ.ά.
Έκδοση: (2016-06-01)

Progress in rituximab for anti⁃MuSK antibody-related myasthenia gravis
ανά: Ting LI, κ.ά.
Έκδοση: (2020-01-01)

Clinical Characteristics of MuSK Antibody-positive Myasthenia Gravis in Taiwan
ανά: Yung-Chuan Huang, κ.ά.
Έκδοση: (2008-07-01)

Anti-MuSK antibodies in seronegative myasthenia gravis: a cause of denervation
ανά: Newsom-Davis, J, κ.ά.
Έκδοση: (2001)

Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5.
ανά: Niks, E, κ.ά.
Έκδοση: (2006)

Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese.
ανά: Yeh, J, κ.ά.
Έκδοση: (2004)

Targeted treatment approaches and pathogenicity of antibody subclasses in MuSK-myasthenia gravis
ανά: Cao, M
Έκδοση: (2021)

Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation
ανά: Fangyi Shi, κ.ά.
Έκδοση: (2024-11-01)

Coexistence of anti-MuSK antibody-positive myasthenia gravis and rheumatoid arthritis
ανά: Amber Eker, κ.ά.
Έκδοση: (2020-08-01)

Regional Features of MuSK Antibody-Positive Myasthenia Gravis in Northeast China
ανά: Zunwei Zhang, κ.ά.
Έκδοση: (2020-10-01)

Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.
ανά: Shiraishi, H, κ.ά.
Έκδοση: (2005)

Myasthenia Crisis as First Presentation of MuSk Positive Myasthenia Gravis: A Case Report
ανά: Dipesh Chhetri, κ.ά.
Έκδοση: (2025-02-01)

Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis
ανά: Lee, J, κ.ά.
Έκδοση: (2016)

Anti-MuSK-Positive Myasthenia Gravis in a Patient with Parkinsonism and Cognitive Impairment
ανά: S. Lanfranconi, κ.ά.
Έκδοση: (2011-01-01)

MuSK Myasthenia Gravis—Potential Pathomechanisms and Treatment Directed against Specific Targets
ανά: Edyta Dziadkowiak, κ.ά.
Έκδοση: (2024-03-01)

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
ανά: Christiane Schneider-Gold, κ.ά.
Έκδοση: (2017-10-01)

Quantitative EMG studies to assess facial muscle atrophy in MuSK antibody positive myasthenia gravis
ανά: Farrugia, M, κ.ά.
Έκδοση: (2007)

Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease
ανά: Aigli G. Vakrakou, κ.ά.
Έκδοση: (2023-07-01)

Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK.
ανά: Vuslat Yilmaz, κ.ά.
Έκδοση: (2015-01-01)

Anti-MuSK antibody positive myasthenia gravis with Graves disease: one case report
ανά: Shan CAO, κ.ά.
Έκδοση: (2019-02-01)

MuSK Myasthenia Gravis in an HIV-infected Chinese old man successfully treated with pyridostigmine
ανά: Yirui Xie, κ.ά.
Έκδοση: (2020-09-01)

Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.
ανά: Deymeer, F, κ.ά.
Έκδοση: (2007)

MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
ανά: Farrugia, M, κ.ά.
Έκδοση: (2006)

Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1.
ανά: Niks, E, κ.ά.
Έκδοση: (2008)

A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression
ανά: Koneczny, I, κ.ά.
Έκδοση: (2024)

Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
ανά: Hoch, W, κ.ά.
Έκδοση: (2001)